Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Transkaryotic Therapies (NasdaqNM:TKTX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
195 Albany Street
Cambridge, MA 02139
Phone: (617) 349-0200
Fax: (617) 491-7903
Email: info@tktx.com
Employees (last reported count): 322
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 46%
·Over the last 6 months:
 · 4 insider buys; 1.92M shares (18.8% of insider shares)
 · 3 insider sells; 46.0K shares
  (0.5% of insider shares)
·Institutional: 62% (114% of float)
(191 institutions)
·Net Inst. Buying: 5.62M shares (+25.65%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Transkaryotic Therapies, Inc. is a biopharmaceutical company developing protein- and cell-based therapeutics for the treatment of a wide range of human diseases. Based on three proprietary development platforms: Gene-Activated proteins, Niche Protein products, and Gene Therapy, the Company is building a broad and renewable product pipeline. Five products emerging from the Company's pipeline have been approved for human clinical testing, including two late-stage products, Dynepo for the treatment of anemia, and Replagal for the treatment of Fabry disease.
More from Market Guide: Expanded Business Description

Financial Summary
Transkaryotic Therapies is a biopharmaceutical company building a product pipeline based on three proprietary development platforms: Gene Activated proteins, Niche Protein products and Gene Therapy. For the six months ended 6/30/01, revenues rose 27% to $1.9 million. Net loss increased 39% to $35.1 million. Results reflect initial revenues from Replagal enzyme replacement therapy, offset by increased development and marketing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Rodman Moorhead, III, 57
Chairman
--  
Richard Selden, M.D., Ph.D., 42
Pres, CEO, Director and Chief Scientific Officer
$864K
Daniel Geffken, 44
CFO, Sr. VP, Sec.
316K
Michael Astrue, 44
Sr. VP of Admin., Gen. Counsel
--  
William Pursley, 47
Sr. VP, Commercial Operations
351K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:TKTXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 11-Apr-2001
$12.50 
Recent Price$30.55 
52-Week High
on 6-Sep-2000
$56.125
Beta1.25 
Daily Volume (3-month avg)488.4K
Daily Volume (10-day avg)340.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-23.5%
52-Week Change
relative to S&P500
+2.6%
Share-Related Items
Market Capitalization$806.4M
Shares Outstanding26.4M
Float14.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$11.74 
Earnings (ttm)-$2.67 
Earnings (mrq)-$0.92 
Sales (ttm)$0.34 
Cash (mrq)$11.23 
Valuation Ratios
Price/Book (mrq)2.60 
Price/EarningsN/A 
Price/Sales (ttm)90.72 
Income Statements
Sales (ttm)$7.66M
EBITDA (ttm)-$73.5M
Income available to common (ttm)-$60.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-21.11%
Return on Equity (ttm)-22.87%
Financial Strength
Current Ratio (mrq)17.97 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$295.7M
Short Interest
As of 8-Aug-2001
Shares Short1.02M
Percent of Float7.1%
Shares Short
(Prior Month)
600.0K
Short Ratio3.42 
Daily Volume299.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.